{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T02:49:48Z","timestamp":1775789388407,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.thromres.2026.109654","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T08:46:09Z","timestamp":1773391569000},"page":"109654","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real world experience of direct oral anticoagulant (DOAC) use in Australian children"],"prefix":"10.1016","volume":"260","author":[{"given":"C.A.","family":"Brown","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Monagle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Wiggins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.thromres.2026.109654_bb0005","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1542\/peds.2009-0768","article-title":"Dramatic increase in venous thromboembolism in children\u2019s hospitals in the United States from 2001 to 2007","volume":"124","author":"Raffini","year":"2009","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.thromres.2026.109654_bb0010","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2021-054649","article-title":"The continued rise of venous thromboembolism across US children\u2019s hospitals","volume":"149","author":"O\u2019Brien","year":"2022","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.thromres.2026.109654_bb0015","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jpeds.2013.10.025","article-title":"Hospital-associated venous thromboembolism in children: incidence and clinical characteristics","volume":"164","author":"Takemoto","year":"2014","journal-title":"J. Pediatr."},{"issue":"22","key":"10.1016\/j.thromres.2026.109654_bb0020","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1182\/bloodadvances.2018024786","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism","volume":"2","author":"Monagle","year":"2018","journal-title":"Blood Adv."},{"issue":"8","key":"10.1016\/j.thromres.2026.109654_bb0025","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.04.004","article-title":"Direct oral anticoagulant agents: pharmacologic profile, indications, coagulation monitoring, and reversal agents","volume":"27","author":"Rose","year":"2018","journal-title":"J. Stroke Cerebrovasc. Dis."},{"issue":"2","key":"10.1016\/j.thromres.2026.109654_bb0030","doi-asserted-by":"crossref","first-page":"e44S","DOI":"10.1378\/chest.11-2292","article-title":"Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Ageno","year":"2012","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.thromres.2026.109654_bb0035","first-page":"892","article-title":"Direct inhibitors of coagulation proteins \u2014 the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?","volume":"102","author":"Laux","year":"2009","journal-title":"Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.thromres.2026.109654_bb0040","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.thromres.2026.109654_bb0045","doi-asserted-by":"crossref","first-page":"38","DOI":"10.18773\/austprescr.2010.017","article-title":"New oral anticoagulant drugs \u2014 mechanisms of action","volume":"33","author":"Brighton","year":"2010","journal-title":"Aust. Prescr."},{"issue":"1","key":"10.1016\/j.thromres.2026.109654_bb0050","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S2352-3026(19)30219-4","article-title":"Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial","volume":"7","author":"Male","year":"2019","journal-title":"Lancet Haematol."},{"issue":"1","key":"10.1016\/j.thromres.2026.109654_bb0055","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1016\/S2352-3026(20)30368-9","article-title":"Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b\/3, non-inferiority trial","volume":"8","author":"Halton","year":"2021","journal-title":"Lancet Haematol."},{"issue":"3","key":"10.1016\/j.thromres.2026.109654_bb0060","doi-asserted-by":"crossref","first-page":"338","DOI":"10.34172\/PS.2020.42","article-title":"Dabigatran versus warfarin for the treatment of pediatric thromboembolism: a pilot randomized trial","volume":"26","author":"Eghbali","year":"2020","journal-title":"Pharm Sci."},{"issue":"1","key":"10.1016\/j.thromres.2026.109654_bb0065","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/S2352-3026(23)00314-9","article-title":"Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial","volume":"11","author":"O\u2019Brien","year":"2024","journal-title":"Lancet Haematol."},{"issue":"4","key":"10.1016\/j.thromres.2026.109654_bb0070","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1080\/10428194.2023.2300719","article-title":"Real-world data of the use of rivaroxaban in pediatric patients with hematologic malignancies","volume":"65","author":"Sultan","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.thromres.2026.109654_bb0075","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ahj.2019.08.002","article-title":"A multi-national trial of a direct oral anticoagulant in children with cardiac disease: design and rationale of the safety of ApiXaban on pediatric heart disease on the preventioN of embolism (SAXOPHONE) study","volume":"217","author":"Payne","year":"2019","journal-title":"Am. Heart J."},{"issue":"7","key":"10.1016\/j.thromres.2026.109654_bb0080","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.jtha.2023.03.005","article-title":"Real-world use of apixaban for the treatment and prevention of thrombosis in children with cardiac disease","volume":"21","author":"Vanderpluym","year":"2023","journal-title":"J. Thromb. Haemost."},{"issue":"10","key":"10.1016\/j.thromres.2026.109654_bb0085","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1182\/bloodadvances.2024015328","article-title":"American Society of Hematology\/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients","volume":"9","author":"Monagle","year":"2025","journal-title":"Blood Adv."},{"issue":"4","key":"10.1016\/j.thromres.2026.109654_bb0090","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J. Thromb. Haemost."},{"issue":"24","key":"10.1016\/j.thromres.2026.109654_bb0095","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.jacc.2023.10.010","article-title":"Apixaban for prevention of thromboembolism in pediatric heart disease","volume":"82","author":"Payne","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"issue":"7","key":"10.1016\/j.thromres.2026.109654_bb0100","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1253\/circj.CJ-08-0931","article-title":"Multicenter and retrospective case study of warfarin and aspirin combination therapy in patients with giant coronary aneurysms caused by Kawasaki disease","volume":"73","author":"Suda","year":"2009","journal-title":"Circ. J."},{"issue":"10","key":"10.1016\/j.thromres.2026.109654_bb0105","first-page":"1598","article-title":"Low-molecular-weight heparin vs warfarin for thromboprophylaxis in children with coronary artery aneurysms after Kawasaki disease: a pragmatic registry trial","volume":"36","author":"Manlhiot","year":"2020","journal-title":"Can. J. Cardiol."},{"issue":"11","key":"10.1016\/j.thromres.2026.109654_bb0110","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.43801","article-title":"DOACs in patients with giant coronary artery aneurysms after Kawasaki disease","volume":"6","author":"Dummer","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"5","key":"10.1016\/j.thromres.2026.109654_bb0115","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/bjh.14003","article-title":"Heavy menstrual bleeding on rivaroxaban \u2014 comparison with apixaban","volume":"176","author":"Myers","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2026.109654_bb0120","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.thromres.2015.07.030","article-title":"Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists","volume":"136","author":"De Crem","year":"2015","journal-title":"Thromb. Res."},{"issue":"5","key":"10.1016\/j.thromres.2026.109654_bb0125","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/pde.15930","article-title":"Efficacy and safety of direct oral anti-coagulants in painful venous malformations in children","volume":"42","author":"Boccara","year":"2025","journal-title":"Pediatr. Dermatol."},{"issue":"7","key":"10.1016\/j.thromres.2026.109654_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2025.103231","article-title":"Direct oral anticoagulant rivaroxaban for secondary prevention of catheter-related thrombosis in children with intestinal failure: real-life data","volume":"9","author":"Hilberath","year":"2025","journal-title":"Res Pract Thromb Haemost."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384826000733?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384826000733?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T02:05:29Z","timestamp":1775786729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384826000733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":26,"alternative-id":["S0049384826000733"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2026.109654","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real world experience of direct oral anticoagulant (DOAC) use in Australian children","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2026.109654","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109654"}}